

Company Registration No: 200601578E
Charity Registration No: 001961
IPC No: HEF0105/G

VIVA FOUNDATION FOR CHILDREN WITH CANCER
(Incorporated in Singapore)

REPORT OF THE DIRECTORS
AND FINANCIAL STATEMENTS

31 DECEMBER 2014

VIVA FOUNDATION FOR CHILDREN WITH CANCER
(Incorporated in Singapore)

31 DECEMBER 2014

CONTENTS	PAGE
Report of the Directors	1 - 2
Statement by Directors	3
Independent Auditors' Report	4 - 5
Statement of Financial Activities	6
Balance Sheet	7
Statement of Cash Flows	8
Notes to the Financial Statements	9 - 26

VIVA FOUNDATION FOR CHILDREN WITH CANCER
(Incorporated in Singapore)

REPORT OF THE DIRECTORS - 31 DECEMBER 2014

The directors are pleased to present their report together with the audited financial statements of Viva Foundation for Children with Cancer (the “Company”) for the financial year ended 31 December 2014.

1 Directors

The directors in office at the date of this report are:

Leong Lai Peng
Christina Ong @ Christina Fu
Kwee Liong Keng
Koh Seow Chuan
Lee Ming San
Kuok Oon Kwong
Mary Ann Wai Sheng Tsao
Tan Wah Yeow
Tan Bee Lan (Appointed on 1 August 2014)
Christopher Wilson (Appointed on 15 January 2015)

2 Directors’ Interest in Shares, Debentures, Dividends and Share Options

The Company is limited by guarantee and does not have a share capital. All matters relating to the issue of shares, debentures, dividends and share options are thus not applicable.

3 Directors’ Contractual Benefits

Since the end of the previous financial year, no director has received or become entitled to receive a benefit which is required to be disclosed under Section 201(8) of the Singapore Companies Act Chapter 50 by reason of a contract made by the Company or a related corporation with the director or with a firm of which he is a member, or with a company in which he has a substantial financial interest.

VIVA FOUNDATION FOR CHILDREN WITH CANCER
(Incorporated in Singapore)

REPORT OF THE DIRECTORS - 31 DECEMBER 2014

4 Independent Auditors

The independent auditors, Moore Stephens LLP, Public Accountants and Chartered Accountants, have expressed their willingness to accept re-appointment.

On behalf of the Board of Directors,


.....
Leong Lai Peng


.....
Lee Ming San

Singapore
22 May 2015

VIVA FOUNDATION FOR CHILDREN WITH CANCER
(Incorporated in Singapore)


STATEMENT BY DIRECTORS

31 DECEMBER 2014

In the opinion of the directors:

- (a) the financial statements as set out on pages 6 to 26 are drawn up so as to give a true and fair view of the state of affairs of the Company as at 31 December 2014 and the results and cash flows of the Company for the financial year then ended; and
- (b) at the date of this statement, there are reasonable grounds to believe that the Company will be able to pay its debts as and when they fall due.

On behalf of the Board of Directors,


.....
Leong Lai Peng


.....
Lee Ming San

Singapore
22 May 2015

INDEPENDENT AUDITORS' REPORT TO THE MEMBERS OF
VIVA FOUNDATION FOR CHILDREN WITH CANCER
(Incorporated in Singapore)

We have audited the accompanying financial statements of Viva Foundation For Children With Cancer (the "Company"), as set out on pages 6 to 26, which comprise the balance sheet as at 31 December 2014, and statement of financial activities and statement of cash flows for the year then ended, and a summary of significant accounting policies and other explanatory information.

Management's Responsibility for the Financial Statements

Management is responsible for the preparation of financial statements that give a true and fair view in accordance with the provisions of the Singapore Companies Act, Chapter 50 (the "Act") and the Singapore Charities Act, Chapter 37 (the "Charities Act") and the Charities Accounting Standard, and for devising and maintaining a system of internal accounting controls sufficient to provide a reasonable assurance that assets are safeguarded against loss from unauthorised use or disposition; and transactions are properly authorised and that they are recorded as necessary to permit the preparation of true and fair profit and loss accounts and balance sheets and to maintain accountability of assets.

Auditors' Responsibility

Our responsibility is to express an opinion on these financial statements based on our audit. We conducted our audit in accordance with Singapore Standards on Auditing. Those standards require that we comply with ethical requirements and plan and perform the audit to obtain reasonable assurance about whether the financial statements are free from material misstatement.

An audit involves performing procedures to obtain audit evidence about the amounts and disclosures in the financial statements. The procedures selected depend on the auditor's judgment, including the assessment of the risks of material misstatement of the financial statements, whether due to fraud or error. In making those risk assessments, the auditor considers internal controls relevant to the entity's preparation of financial statements that give a true and fair view in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the entity's internal controls. An audit also includes evaluating the appropriateness of accounting policies used and the reasonableness of accounting estimates made by management, as well as evaluating the overall presentation of the financial statements.

We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our audit opinion.

INDEPENDENT AUDITORS' REPORT TO THE MEMBERS OF

**VIVA FOUNDATION FOR CHILDREN WITH CANCER
(Incorporated in Singapore)**

(cont'd)

Opinion


In our opinion, the financial statements are properly drawn up in accordance with the provisions of the Act, the Charities Act and Charities Accounting Standard, so as to give a true and fair view of the state of affairs of the Company as at 31 December 2014 and the results, and cash flows of the Company for the year ended on that date.

Report on Other Legal and Regulatory Requirements

During the course of our audit, nothing has come to our attention that causes us to believe that during the year:

- a. The use of the donation moneys was not in accordance with the objectives of the Company as required under regulation 16 of the Charities (Institutions of a Public Character) Regulations; and
- b. The Company has not complied with the requirements of regulation 15 (Fund-raising expenses) of the Charities (Institutions of a Public Character) Regulations.

In our opinion, the accounting and other records required by the Act to be kept by the Company have been properly kept in accordance with the provisions of the Act.



Moore Stephens LLP
Public Accountants and
Chartered Accountants

Singapore
22 May 2015

VIVA FOUNDATION FOR CHILDREN WITH CANCER
(Incorporated in Singapore)

STATEMENT OF FINANCIAL ACTIVITIES

FOR THE FINANCIAL YEAR ENDED 31 DECEMBER 2014

	<u>Note</u>	<u>2014</u> S\$	<u>2013</u> S\$
<u>Unrestricted General Funds</u>			
Income			
Income from generated funds			
- Voluntary income	4	953,020	419,183
- Investment income	4	15,474	6,164
- Activities for generating funds	4	580,285	-
Income from charitable activities	5	147,921	113,357
Other income	6	587	78,448
Total income		1,697,287	617,152
Expenditures			
Cost of generating funds			
- Cost of generating voluntary income	7	58,832	392,917
- Fundraising activities	7	61,839	-
Charitable activities	8	1,233,069	199,515
Governance costs	9	751,292	808,835
Total expenditures		2,105,032	1,401,267
Net expenditure before tax expense		(407,745)	(784,115)
Tax expense	11	-	-
Net expenditure		(407,745)	(784,115)
Gross transfers between funds		-	-
Net movement in funds		(407,745)	(784,115)
Reconciliation of funds			
Total funds brought forward	19	27,525,957	28,310,072
Total funds carried forward^(a)		27,118,212	27,525,957
 (a) Total funds carried forward			
		<u>2014</u> S\$	<u>2013</u> S\$
- Available fund balance		4,825,712	4,751,457
- Donated space (Note 12) (this asset could not be monetised)		22,292,500	22,774,500
		27,118,212	27,525,957

The accompanying notes form an integral part of the financial statements

VIVA FOUNDATION FOR CHILDREN WITH CANCER
(Incorporated in Singapore)

BALANCE SHEET

AS AT 31 DECEMBER 2014

	<u>Note</u>	<u>2014</u> S\$	<u>2013</u> S\$
Non-Current Asset			
Property and equipment	12	22,614,020	23,177,339
Current Assets			
Trade receivables	13	1,300	7,420
Other receivables and prepayments	14	144,180	126,536
Cash and cash equivalents	15	4,423,039	4,767,328
		4,568,519	4,901,284
Current Liabilities			
Accrued expenses	16	11,686	22,035
Deferred income	17	-	484,000
Deposits received	18	48,892	46,631
Other payables		3,749	-
		64,327	552,666
Net Current Assets		4,504,192	4,348,618
Total Assets Less Current Liabilities		27,118,212	27,525,957
Funds of Charity			
<u>Unrestricted Funds</u>			
General funds ^(a)	19	27,118,212	27,525,957
Total Charity Funds		27,118,212	27,525,957

(a) General funds

	<u>2014</u> S\$	<u>2013</u> S\$
- Available fund balance	4,825,712	4,751,457
- Donated space (Note 12) (this asset could not be monetised)	22,292,500	22,774,500
	27,118,212	27,525,957

The accompanying notes form an integral part of the financial statements

VIVA FOUNDATION FOR CHILDREN WITH CANCER
(Incorporated in Singapore)

STATEMENT OF CASH FLOWS

FOR THE FINANCIAL YEAR ENDED 31 DECEMBER 2014

	<u>2014</u>	<u>2013</u>
	S\$	S\$
Cash Flows from Operating Activities		
Net expenditure before tax expense	(407,745)	(784,115)
Adjustments for:		
Non-refundable purchase tax	5,252	12,936
Depreciation of property and equipment	531,180	530,565
Interest income	(15,474)	(6,164)
Operating cash flows before changes in working capital	113,213	(246,778)
Trade receivables	6,120	2,930
Other receivables and prepayments	(17,644)	442,037
Accrued expenses	(10,349)	4,282
Other payables	3,749	-
Deferred income	(484,000)	472,035
Deposits received	2,261	17,127
Net cash flows (used in)/ from operations	(386,650)	691,633
Non-refundable purchase tax paid	(5,252)	(12,936)
Net cash flows (used in)/from operating activities	(391,902)	678,697
Cash Flows from Investing Activities		
Purchase of equipment	(1,847)	(7,352)
Reimbursement for property and equipment by third party	33,986	-
Interest received	15,474	6,164
Net cash flows from/(used in) investing activities	47,613	(1,188)
Net increase/(decrease) in cash and cash equivalents	(344,289)	677,509
Cash and cash equivalents at the beginning of the year	4,767,328	4,089,819
Cash and cash equivalents at the end of the year (Note 15)	4,423,039	4,767,328

The accompanying notes form an integral part of the financial statements

VIVA FOUNDATION FOR CHILDREN WITH CANCER
(Incorporated in Singapore)

NOTES TO THE FINANCIAL STATEMENTS - 31 DECEMBER 2014

These notes form an integral part of and should be read in conjunction with the accompanying financial statements.

1 General Information

Viva Foundation for Children with Cancer (the “Company”) is a company limited by guarantee, domiciled and incorporated in Singapore. The address of the Company’s registered office and principal place of business is 8 Sinaran Drive #03-01 Novena Specialist Center Singapore 307470.

The principal activity of the Company is to fund, support and establish programmes which will improve the treatment and cure of childhood cancer. There were no significant changes in the Company’s principal activity during the financial year.

These financial statements were authorised for issue in accordance with a resolution of the Board of Directors of the Company on the date of the Statement by Directors.

2 Significant Accounting Policies

(a) Basis of Preparation

The financial statements, which are expressed in Singapore dollars, have been prepared in accordance with the provisions of the Singapore Companies Act, Chapter 50, Charities Act, Chapter 37 (the “Act”) and Charities Accounting Standard (“CAS”). The accounting policies of the Company are consistent with the requirements of the CAS and are applied consistently to similar transactions, other events and conditions. The financial statements have been prepared under the historical cost convention, except as disclosed in the accounting policies below.

The preparation of financial statements in conformity with CAS requires management to exercise its judgment in the process of applying the Company’s accounting policies. It also requires the use of accounting estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements, and the reported amounts of revenues and expenses during the financial year. Although these estimates are based on management’s best knowledge of current events and actions, actual results may ultimately differ from those estimates. The areas involving a higher degree of judgment or complexity are disclosed in Note 3 to the financial statements.

(b) Fund Accounting

Monies received for specific purposes, including transfers from the general fund, are credited directly to the respective fund financial statements. These include restricted funds and unrestricted funds. Restricted funds are funds held by the Company that can only be applied for specific purposes. These funds are subject to specific trusts which may be declared by the donors or with their authority or created through legal process but are still within the wider objects of the Company. Unrestricted funds are expendable at the discretion of the Company’s Board of Directors in furtherance of the Company’s objects. Designated fund is part of the unrestricted funds earmarked for a particular project. The designation is for administrative purposes only and does not restrict the Board’s discretion to apply the fund.

VIVA FOUNDATION FOR CHILDREN WITH CANCER
(Incorporated in Singapore)

NOTES TO THE FINANCIAL STATEMENTS - 31 DECEMBER 2014

2 Significant Accounting Policies (cont'd)

(b) Fund Accounting (cont'd)

Income and expenditure relating to specific funds are accounted for directly in the funds to which they relate. Assets and liabilities of the specific funds are pooled in the balance sheet.

Funds received for the specific purposes such as purchase of depreciable assets are taken to relevant restricted fund account. The relevant fund will be reduced over the useful life of the asset in line with its depreciation. Depreciation is charged to the relevant designated funds where the asset is held.

(c) Property and Equipment

Property and equipment are initially stated at cost. Subsequent to initial recognition, property and equipment are stated at cost less accumulated depreciation. The property received for use in the form of gifts in-kind is initially stated at fair value, based on revaluation done by independent professional valuers. Such fair value is taken to statement of financial activities.

The cost of an item of property and equipment includes its purchase price and any cost that is directly attributable to bringing the asset to the location and condition necessary for it to be capable of operating in the manner intended by management. Irrecoverable GST allocable to property, plant and equipment and to other items shall be included in their cost where it meets the criteria for capitalisation and significant. The projected cost of dismantlement, removal or restoration is also included as part of the cost of property and equipment if the obligation for the dismantlement, removal and restoration is incurred as a consequence of acquiring or using the asset.

The cost of an item of plant and equipment is recognised as an asset if, and only if it is probable that future economic benefits associated with the item will flow to the Company and the cost of the item can be measured reliably. When significant parts of property, plant and equipment are required to be replaced at intervals (e.g. the roof of a building), the cost of replacing such an item when that cost is incurred is added to the carrying amount of the item if the recognition criteria are met. The cost of day-to-day servicing of an item of plant and equipment is recognised as expenditure in the statement of financial activities in the period in which the costs are incurred. Property and equipment shall not be revalued and are not required to be assessed for impairment

The gain or loss on the disposal of an asset shall be accounted for in net income or expenditure in the Statement of Financial Activities in the period in which the disposal occurs as the difference between the net sale proceeds and the net carrying amount of the asset.

Depreciation of an asset begins when it is available for use, i.e. when it is in the location and condition necessary for it to be capable of operating in the manner intended by management. Depreciation of an asset ceases when the asset is derecognised. Depreciation does not cease when the asset becomes idle or is retired from active use unless the asset is fully depreciated.

VIVA FOUNDATION FOR CHILDREN WITH CANCER
(Incorporated in Singapore)

NOTES TO THE FINANCIAL STATEMENTS - 31 DECEMBER 2014

2 Significant Accounting Policies (cont'd)

(c) Plant and Equipment (cont'd)

Depreciation is calculated on a straight-line basis to write off the cost (net of residual value) of the property and equipment over their estimated useful lives. The estimated useful lives are as follows:

Leasehold building	- 50 years
Renovation	- 10 years
Furniture and fixtures	- 5 years
Computer and office equipment	- 3 years

The depreciation charge for each period is recognised as expenditure in the statement of financial activities unless another section of the CAS requires it to be included in the carrying amount of another asset. The residual values, estimated useful lives and depreciation method of property and equipment are reviewed and adjusted, as appropriate, at each balance sheet date. The effects of any revisions are recognised in the statement of financial activities for the financial year in which the changes arise. The carrying amount of the plant and equipment at the date of revision or changes is depreciated over the revised remaining useful lives.

(d) Trade and Other Receivables

Trade and other receivables excluding prepayments are initially recognised at their transaction price, excluding transaction costs, if any. Transaction costs are recognised as expenditure in the statement of financial activities as incurred. Prepayments are initially recognised at the amount paid in advance for the economic resources expected to be received in the future.

After initial recognition, trade and other receivables, excluding prepayments, are subsequently measured at cost less any accumulated impairment losses. Prepayments are subsequently measured at the amount paid less the economic resources received or consumed during the financial year.

Financial assets (consisting of cash and cash equivalents, and trade and other receivables) and prepayments are derecognised when the contractual rights to receive cash flows from the assets have expired or have been transferred and the Company has transferred substantially all risks and rewards of ownership. On derecognition of financial assets in its entirety, the difference between the carrying amount and the sum of the consideration received is recognised in the statement of financial activities.

Impairment

The Company assesses at each balance sheet date whether there is objective evidence that a financial asset or a group of financial assets is impaired and recognises an impairment loss (i.e. expenditure) immediately in the statement of financial activities when such evidence exists.

VIVA FOUNDATION FOR CHILDREN WITH CANCER
(Incorporated in Singapore)

NOTES TO THE FINANCIAL STATEMENTS - 31 DECEMBER 2014

2 Significant Accounting Policies (cont'd)

(d) Trade and Other Receivables (cont'd)

Impairment (cont'd)

To determine whether there is objective evidence that an impairment loss on financial assets has been incurred, the Company considers observable data that come to the attention of the Company. The impairment loss is the difference between the carrying amount of the financial asset and the undiscounted future cash flows (excluding unearned interest in the case of interest-bearing assets) that the Company expects to receive from the financial asset.

The previously recognised impairment loss is subsequently reversed if the amount of the impairment loss decreases and the decrease is related objectively to an event occurring after the impairment was recognised (such as an improvement in the debtor's financial condition). The previously recognised impairment loss is reversed to the extent that the carrying amount of the financial assets, net of any allowance account that exceeds what the carrying amount would have been, had the impairment not previously been recognised. The reversal of impairment loss is recognised in the statement of financial activities.

(e) Cash and Cash Equivalents

Cash and cash equivalents comprise cash on hand and at bank and fixed deposits, which are short term, highly liquid investments that are readily convertible to known amounts of cash and are subject to insignificant risk of changes in value.

(f) Financial Liabilities

Financial liabilities are recognised on the balance sheet when, and only when the Company became a party to the contractual provisions of the financial instrument. The Company derecognises financial liabilities when, and only when the Company's obligations are discharged, cancelled or expired.

(g) Other Payables and Accruals

Other payables, excluding accruals, are recognised at their transaction price, excluding transaction costs, if any, both at initial recognition and at subsequent measurement. Transaction costs are recognised as expenditure in the statement of financial activities as incurred. Accruals are recognised at the best estimate of the amount payable.

VIVA FOUNDATION FOR CHILDREN WITH CANCER
(Incorporated in Singapore)

NOTES TO THE FINANCIAL STATEMENTS - 31 DECEMBER 2014

2 Significant Accounting Policies (cont'd)

(h) Revenue Recognition

Revenue including donations, gifts and grants that provide core funding or are of general nature are recognised when there is (a) entitlement (b) certainty and (c) sufficient reliability of measurement. Such income is only deferred when: the donor specifies that the grant of donation must only be used in future accounting periods; or the donor has imposed conditions which must be met before the Company has unconditional entitlement.

Donations

Revenue from donations and corporate cash sponsorships are accounted for when received, except for committed donations and corporate cash sponsorships that are recorded when the commitments are fulfilled.

Grants

Grants received to cover a particular expenditure or programme are accounted for as income upon receipt of notification of the grant award and when the criteria of entitlement, certainty and measurability are met. When conditions are attached, they must be fulfilled before the Foundation has unconditional entitlement to the income. The income is deferred as a liability where uncertainty exists as to whether the Foundation can meet the conditions and is recognised as income when there is sufficient evidence that the conditions imposed can be met.

Others

Revenue from events such as St. Jude – VIVA Forum is recognised when the event takes place.

Interest income is recognised on a time proportion basis using the effective interest method.

(i) Gifts In Kind

A gift in kind is included in the statement of financial activities based on an estimate of the fair value at the date of the receipt of the gift of the non-monetary asset or the grant of a right to the monetary asset. The gift is recognised if the amount of the gift can be measured reliably and there is no uncertainty that it will be received.

(j) Expenditure

All expenditures are accounted for on an accrual basis and have been classified under headings that aggregate all costs related to that activity. Cost comprises direct expenditure including direct staff costs attributable to the activity.

VIVA FOUNDATION FOR CHILDREN WITH CANCER
(Incorporated in Singapore)

NOTES TO THE FINANCIAL STATEMENTS - 31 DECEMBER 2014

2 Significant Accounting Policies (cont'd)

(k) Expenditure (cont'd)

Cost of generating funds

The cost of generating funds are those costs attributable to generating income for the Foundation, other than those costs incurred in undertaking charitable activities in the furtherance of the Foundation's objects.

Charitable activities

Expenditure of charitable activities comprise all costs incurred in the pursuit of the charitable objects of the Foundation. Those costs, where not wholly attributable, are apportioned between the categories of charitable expenditure. The total costs of each category of charitable expenditure, therefore, include an apportionment of support cost, where possible.

Governance costs

Governance costs include the costs of governance arrangements, which relate to the general running of the Company as opposed to the direct management functions inherent in generating funds, service delivery and programme or project work. Expenditure on the governance of the charity will normally include both direct and related support costs which include internal and external audit, apportioned manpower costs and general costs in supporting the governance activities, legal advice for governing board members, and costs associated with constitutional and statutory requirements.

Other expenditure

Other expenditure includes the payment of any expenditure that the Company has not been able to analyse within the main expenditure categories.

(k) Employee Benefits

Defined contribution plans

Defined contribution plans are post-employment benefit plans under which the Company pays fixed contributions into separate entities such as the Central Provident Fund, and will have no legal or constructive obligation to pay further contributions if any of the funds do not hold sufficient assets to pay all employee benefits relating to employee services in the current period and preceding financial years. The Company's contributions to defined contribution plans are recognised in the financial year to which they relate.

Employee leave entitlement

Employee entitlements to annual leave and long service leave are recognised when they accrue to employees. Accrual is made for the estimated liability for annual leave and long-service leave as a result of services rendered by employees up to the balance sheet date.

VIVA FOUNDATION FOR CHILDREN WITH CANCER
(Incorporated in Singapore)

NOTES TO THE FINANCIAL STATEMENTS - 31 DECEMBER 2014

2 Significant Accounting Policies (cont'd)

(l) Currency Translation

Functional and presentation currency

Items included in the financial statements of the Company are measured using the currency of the primary economic environment in which the entity operates (the “functional currency”). The financial statements are presented in Singapore dollars (“S\$”), which is the Company’s functional and presentation currency, as it best reflects the economic substance of the underlying events and circumstances relevant to the Company. The financial statements are presented in S\$ and all values in particular on the surplus for the year are rounded to the nearest dollars (\$) except when otherwise indicated.

(m) Income Tax

The Company is an approved charity under the Charities Act, Chapter 37 and an Institution of a Public Character under the Income Tax Act, Chapter 134. No provision for taxation has been made in the financial statements as the Company is a registered charity with income tax exemption.

3 Critical Accounting Estimates, Assumptions and Judgements

Estimates, assumptions and judgements are continually evaluated and are based on historical experience and other factors, including expectations of future events that are believed to be reasonable under the circumstances.

The Company makes judgement, estimates and assumptions concerning the future. There are no critical judgements that have a significant risk of causing a material adjustment to the carrying amounts of assets and liabilities. The resulting accounting estimates will, by definition, seldom equal the related actual results. The estimates and assumptions that have a significant risk of causing a material adjustment to the carrying amounts of assets and liabilities are as follows:

Critical Accounting Estimates and Assumptions

Estimated useful lives of property and equipment

The Company’s management determines the useful lives and related depreciation charges for its property and equipment to be between 3 and 50 years. The estimate is based on the historical experience of the actual useful lives of property and equipment of similar nature and functions. Any changes to the Company’s planned use of property and equipment, could result in the actual useful lives differing from the Company’s current estimates.

In those cases where the Company determines that the useful lives of property and equipment should be shortened or extended, the Company would depreciate the net book value in excess of the estimated salvage value over its revised remaining useful lives. The carrying amount of the Company’s depreciable property and equipment as at 31 December 2014 was S\$22,614,020 (2013: S\$23,177,339).

VIVA FOUNDATION FOR CHILDREN WITH CANCER
(Incorporated in Singapore)

NOTES TO THE FINANCIAL STATEMENTS - 31 DECEMBER 2014

3 Critical Accounting Estimates, Assumptions and Judgments (cont'd)

Critical Accounting Estimates and Assumptions (cont'd)

Estimated useful lives of property and equipment (cont'd)

A 10% difference in the expected useful life of these assets from management's estimates would result in increasing and decreasing the Company's statement of financial activities for the year by approximately S\$53,120 (2013: S\$53,060).

4 Income from Generated Funds

	<u>2014</u> S\$	<u>2013</u> S\$
<i>Unrestricted Funds:</i>		
<u>Voluntary income</u>		
Donations - general	869,786	419,183
Donations - in kind	5,274	-
	875,060	419,183
Government grant:		
- Care and Share Movement Grant	77,960	-
	953,020	419,183
<u>Investment income</u>		
Interest from bank balances	15,474	6,164
	580,285	-
<u>Activities for generating funds</u>		
Fundraising - Charity dinner	580,285	-

5 Income from Charitable Activities

	<u>2014</u> S\$	<u>2013</u> S\$
<i>Unrestricted Funds:</i>		
Registration receipt for St. Jude - VIVA Forum	147,921	113,357
	147,921	113,357

6 Other Income

	<u>2014</u> S\$	<u>2013</u> S\$
<i>Unrestricted Funds:</i>		
Refund of donation	-	78,448
Others	587	-
	587	78,448

VIVA FOUNDATION FOR CHILDREN WITH CANCER
(Incorporated in Singapore)

NOTES TO THE FINANCIAL STATEMENTS - 31 DECEMBER 2014

7 Costs of Generating Funds

	<u>2014</u>	<u>2013</u>
	S\$	S\$
<i>Unrestricted Funds:</i>		
<u>Cost of generating voluntary income</u>		
- Non-claimable GST input tax	5,252	12,936
- Maintenance fees	53,580	129,981
- Cash donation	-	250,000
	58,832	392,917
 <u>Fundraising expenses</u>		
Fundraising expenses	61,839	-

In prior year, a cash donation of S\$250,000 was made to Children's Cancer Foundation for Place for Academic Learning and Support (PALS).

8 Charitable Activities

	<u>2014</u>	<u>2013</u>
	S\$	S\$
<i>Unrestricted Funds:</i>		
<u>Direct operating costs</u>		
Accommodation	36,378	32,065
Fellowship grants	3,604	4,599
Honoraria	9,519	10,241
Printing and publication	15,836	15,735
Transportation	68,831	64,798
Venue expense	67,643	53,456
Others	31,258	18,621
	233,069	199,515
Cash gift	1,000,000	-
	1,233,069	199,515

These amounts, other than cash donation, were incurred for St. Jude - VIVA Forum held during the current financial year ended 31 December 2014.

The cash gift of S\$1,000,000 was made to the National University of Singapore to fund its cancer immunotherapy clinical research.

VIVA FOUNDATION FOR CHILDREN WITH CANCER
(Incorporated in Singapore)

NOTES TO THE FINANCIAL STATEMENTS - 31 DECEMBER 2014

9 Governance Costs

	<u>2014</u>	<u>2013</u>
	S\$	S\$
<i>Unrestricted Funds:</i>		
General and administrative expenses	48,208	65,745
Audit fees - current year	8,000	8,000
Depreciation	531,180	530,565
Professional fees	-	19,846
Salaries and related costs (Note 10)	163,904	184,679
	751,292	808,835

All directors and other members of key management personnel do not receive any remuneration. There are no other financial services paid to the auditors of the Company.

10 Employee Benefits

	<u>2014</u>	<u>2013</u>
	S\$	S\$
<u>Salaries and related costs</u>		
Short-term employee benefits:		
- Gross salaries and bonuses	146,240	149,625
- Other staff benefits	602	11,020
- Post employment benefits (Defined Contribution Plans)	17,062	24,034
	163,904	184,679

The above support costs are allocated to governance costs based on time spent in governance activities and is consistent between financial years.

11 Income Tax

The Company is an approved charity under the Charities Act, Chapter 37 and an Institution of a Public Character under the Income Tax Act, Chapter 134. No provision for taxation has been made in the financial statements as the Company is a registered charity with income tax exemption. As required by the Charities Act (Chapter 37), the total fund-raising and sponsorship expenses of the Company for the financial year did not exceed 30% of the total gross receipts from fund-raising and sponsorship for that financial year.

VIVA FOUNDATION FOR CHILDREN WITH CANCER
(Incorporated in Singapore)

NOTES TO THE FINANCIAL STATEMENTS - 31 DECEMBER 2014

12 Property and Equipment

	<u>Leasehold building</u> S\$	<u>Computer</u> S\$	<u>Office equipment</u> S\$	<u>Furniture and fixtures</u> S\$	<u>Renovation</u> S\$	<u>Total</u> S\$
2014						
<u>Cost</u>						
At 1 January	24,100,000	7,717	1,997	7,664	464,162	24,581,540
Additions	-	1,847	-	-	-	1,847
Disposals	-	-	-	-	(33,986)	(33,986)
At 31 December	24,100,000	9,564	1,997	7,664	430,176	24,549,401
<u>Accumulated depreciation</u>						
At 1 January	1,325,500	6,713	1,468	1,661	68,859	1,404,201
Charge for the year	482,000	1,404	264	1,533	45,979	531,180
At 31 December	1,807,500	8,117	1,732	3,194	114,838	1,935,381
<u>Net book value</u>						
At 31 December	22,292,500	1,447	265	4,470	315,338	22,614,020
2013						
<u>Cost</u>						
At 1 January	24,100,000	7,717	1,204	7,664	457,603	24,574,188
Additions	-	-	793	-	6,559	7,352
At 31 December	24,100,000	7,717	1,997	7,664	464,162	24,581,540
<u>Accumulated depreciation</u>						
At 1 January	843,500	5,924	1,204	128	22,880	873,636
Charge for the year	482,000	789	264	1,533	45,979	530,565
At 31 December	1,325,500	6,713	1,468	1,661	68,859	1,404,201
<u>Net book value</u>						
At 31 December	22,774,500	1,004	529	6,003	395,303	23,177,339

VIVA FOUNDATION FOR CHILDREN WITH CANCER
(Incorporated in Singapore)

NOTES TO THE FINANCIAL STATEMENTS - 31 DECEMBER 2014

12 Property and Equipment (cont'd)

The Company entered into an agreement on 10 February 2011 and received a donation of space located at 8 Sinaran Drive, 3rd level, Novena Specialist Centre, Singapore (“Community Space”). As it is a donated civic and community institution space, it cannot be monetised and rented out for profit. The leasehold building was initially carried at fair value at the balance sheet date based on independent professional valuations by a valuer who had the appropriate qualification and recent experience in the valuation of properties in the relevant locations. In determining the fair value, the valuer had employed valuation techniques such as the market comparison method and estimates have been applied towards the valuation method.

An independent professional valuer, Knight Frank, one of the leading real estate consultancy firms in Singapore has been engaged, to determine the fair value of the leasehold building as at 31 December 2014. The independent professional valuer has, based on the comparative sales method, considered the prevailing market conditions and other relevant factors and is of the opinion that the value of the leasehold property with vacant possession is valued at S\$33.43 million as at 31 December 2014 (2013: S\$33.43 million).

13 Trade Receivables

	<u>2014</u>	<u>2013</u>
	S\$	S\$
Third parties	1,300	7,420

14 Other Receivables and Prepayments

	<u>2014</u>	<u>2013</u>
	S\$	S\$
<u>Other receivables</u>		
Deposits	19,769	12,241
Due from third parties	45,577	90,828
	65,346	103,069
 Prepayments	 78,834	 23,467
	144,180	126,536

Included in the deposits is an amount of S\$14,477 (2013: S\$6,701) paid for the venue for the St. Jude - VIVA Forum to be held in March 2015.

The amount due from third parties relates to the reimbursement for running costs due from Children Cancer Foundation (“CCF”), Singapore Cord Blood Bank Limited (“SCBB”) and Bone Marrow Donor Programme (“BMDP”). Under the terms stated in the license agreements entered with the Company, CCF, SCBB and BMDP have agreed to co-share such running costs incurred for the community space which is owned by the Company. The amount due from third parties is unsecured, interest-free and repayable on demand.

VIVA FOUNDATION FOR CHILDREN WITH CANCER
(Incorporated in Singapore)

NOTES TO THE FINANCIAL STATEMENTS - 31 DECEMBER 2014

15 Cash and Cash Equivalents

	<u>2014</u>	<u>2013</u>
	S\$	S\$
Cash on hand	109	500
Cash at bank	2,911,575	3,266,828
Fixed deposits placed with financial institutions	1,511,355	1,500,000
	4,423,039	4,767,328

The effective interest rate on the interest earning bank balance is 0.99% per annum (2013: 0.19%).

The interest rate earned on fixed deposits is at 0.64% to 0.94% (2013: 0.57% to 0.8%) per annum with maturity dates ranging from 3 to 6 months (2013: 3 to 6 months).

16 Accrued Expenses

	<u>2014</u>	<u>2013</u>
	S\$	S\$
Accruals	11,686	21,215
Others	-	820
	11,686	22,035

17 Deferred Income

	<u>2014</u>	<u>2013</u>
	S\$	S\$
Third parties	-	484,000
	-	484,000

In 2013, the Company received S\$5,000 and S\$479,000 deferred income in relation to the St. Jude - VIVA Forum and "Love Gala" charity dinner respectively held in the financial year ended 31 December 2014. The deferred income of S\$484,000 as at 31 December 2013 was recognised as income in the financial year ended 31 December 2014.

18 Deposits Received

	<u>2014</u>	<u>2013</u>
	S\$	S\$
Third parties	48,892	46,631
	48,892	46,631

As at 31 December 2014, the Company has received deposits of S\$48,892 (2013: S\$46,631) in relation to the terms stated in the license agreements entered with Children Cancer Foundation ("CCF"), Singapore Cord Blood Bank Limited ("SCBB") and Bone Marrow Donor Programme ("BMDP").

VIVA FOUNDATION FOR CHILDREN WITH CANCER
(Incorporated in Singapore)

NOTES TO THE FINANCIAL STATEMENTS - 31 DECEMBER 2014

19 Funds of Charity

	<u>2014</u>	<u>2013</u>
	S\$	S\$
<i>Unrestricted Funds</i>		
General fund		
- Available fund balance	4,825,712	4,751,457
- Donated space (Note 12) (this asset could not be monetised)	22,292,500	22,774,500
	<u>27,118,212</u>	<u>27,525,957</u>

Movements of the funds during the current and previous financial year are disclosed as follows:

	<u>Unrestricted Funds</u> S\$
Funds balance at 1 January 2014	27,525,957
Total income	1,697,287
Total expenditure	(2,105,032)
Net income	(407,745)
Funds balance at 31 December 2014	<u>27,118,212</u>
Funds balance at 1 January 2013	28,310,072
Total income	617,152
Total expenditure	(1,401,267)
Net income	(784,115)
Funds balance at 31 December 2013	<u>27,525,957</u>

20 Tax Exempt Receipts

The Company enjoys a concessionary tax treatment whereby qualifying donors are granted a 2.5 times tax deduction for the donations made to the Company.

	<u>2014</u>	<u>2013</u>
	S\$	S\$
Tax exempt receipts issued for donations collected	<u>1,337,576</u>	<u>292,021</u>

VIVA FOUNDATION FOR CHILDREN WITH CANCER
(Incorporated in Singapore)

NOTES TO THE FINANCIAL STATEMENTS - 31 DECEMBER 2014

21 Other Charity Funds

The Company held donation drives to raise funds for specific projects indicated in (i), (ii), (iii), (iv), (v) and (vi). The donations raised and expended in respect of these specific projects are shown below.

The donations contributed by the donors were designated for specific purposes and the money was paid directly to the beneficiaries. Therefore, these donations and the amounts expended below are not reflected in the financial statements of the Company.

	Donations Received	Government Matching grant
	S\$	S\$
<u>31 December 2014</u>		
National University of Singapore		
- Children Cancer Centre Fund (“CCCEF”) (i)		
Balance at 1 January	1,564,086	2,652,999
<u>Add:</u>		
Investment income	9,086	272,809
Balance at 31 December	<u>1,573,172</u>	<u>2,925,809</u>
National University Hospital		
- Health Research Endowment Fund (“HREF”) (ii)		
Balance at 1 January	3,188,403	3,000,000
<u>Add/(Less):</u>		
Other income	5,277	-
Expenditures	(314,236)	-
Balance at 31 December	<u>2,879,444</u>	<u>3,000,000</u>
National University of Singapore		
- Viva Paediatric Oncology Fund (“VPOF”) (iii)		
Balance at 1 January	7,226,379	15,517,821
<u>Add/(Less):</u>		
Other income	15,708	1,595,727
Expenditures	(1,416,538)	(23,719)
Balance at 31 December	<u>5,825,549</u>	<u>17,089,829</u>

VIVA FOUNDATION FOR CHILDREN WITH CANCER
(Incorporated in Singapore)

NOTES TO THE FINANCIAL STATEMENTS - 31 DECEMBER 2014

21 Other Charity Funds (cont'd)

	<u>Donations Received</u> S\$	<u>Government Matching grant</u> S\$
<u>31 December 2014 (cont'd)</u>		
National University of Singapore		
- Education and Research Fund ("ERF")^(iv)		
Balance at 1 January	-	918,388
<u>Add/(Less):</u>		
Investment income	-	15,990
Balance at 31 December	-	934,377
National University of Singapore		
- Immunotherapy Fund ("IF")^(v)		
Balance at 1 January	-	-
<u>Add/(Less):</u>		
Initial fund established	1,000,000	-
Expenditures	(169,454)	-
Balance at 31 December	830,546	-
National University of Singapore		
- Centre for Translational Research in Acute Leukaemia		
("CenTRAL")^(vi)		
Balance at 1 January	-	-
<u>Add/(Less):</u>		
Initial fund established	1,000,000	-
Balance at 31 December	1,000,000	-

VIVA FOUNDATION FOR CHILDREN WITH CANCER
(Incorporated in Singapore)

NOTES TO THE FINANCIAL STATEMENTS - 31 DECEMBER 2014

21 Other Charity Funds (cont'd)

	<u>Donations Received</u> S\$	<u>Government Matching grant</u> S\$
<u>31 December 2013</u>		
National University of Singapore		
- Children Cancer Centre Fund ("CCCEF") (i)		
Balance at 1 January	1,549,502	2,380,398
<u>Add:</u>		
Investment income	14,584	272,601
Balance at 31 December	1,564,086	2,652,999
National University Hospital		
- Health Research Endowment Fund ("HREF") (ii)		
Balance at 1 January	3,183,072	3,000,000
<u>Add/(Less):</u>		
Other income	19,962	-
Expenditures	(14,631)	-
Balance at 31 December	3,188,403	3,000,000
National University of Singapore		
- Viva Paediatric Oncology Fund ("VPOF") (iii)		
Balance at 1 January	9,026,413	13,926,287
<u>Add/(Less):</u>		
Other income	26,401	1,595,277
Expenditures	(1,826,435)	(3,743)
Balance at 31 December	7,226,379	15,517,821
National University of Singapore		
- Education and Research Fund ("ERF") (iv)		
Balance at 1 January	78,588	824,021
<u>Add/(Less):</u>		
Investment income	(140)	94,367
Refund of donation	(78,448)	-
Balance at 31 December	-	918,388

- (i) Children Cancer Centre - The funds were donated to the National University of Singapore – Children Cancer Centre Fund to establish a children’s cancer centre, now known as the Viva-University Children’s Cancer Centre (VUC) at the National University Hospital which would be the centre of excellence for the treatment and cure of childhood cancer particularly leukaemia; the training and hiring of doctors, nurses, technical and administrative personnel from Singapore and the region; clinical and translational research; cellular therapy and stem cell transplantation. The funding is by Viva Foundation with S\$822,000 on non-asset items and by Singapore Totalisator Board with a maximum of up to S\$4.2 million.

VIVA FOUNDATION FOR CHILDREN WITH CANCER
(Incorporated in Singapore)

NOTES TO THE FINANCIAL STATEMENTS - 31 DECEMBER 2014

21 Other Charity Funds (cont'd)

- (ii) Health Research Endowment Fund - The funds were donated to the National University Hospital to establish the Mrs. Lee Kong Chian Memorial Chair, for Director of Advanced Clinical and Translational Research for Childhood Leukaemia and Cellular Therapy under the Viva Children's Cancer Program. The donation of S\$3 million was received from Lee Foundation, via Viva Foundation and was matched by the Ministry of Health with S\$3 million in two payments received December 2006 and March 2007. The money was used as a bridging loan to support the setting up for Viva University Children's Cancer Centre.
- (iii) Viva Paediatric Oncology Fund – The Viva Paediatric Oncology Fund has been established with an expendable gift of S\$12 million dollars from the Goh Foundation with matching grant from the Singapore Government to Yong Loo Lin School of Medicine, NUS. The fund shall be used to advance paediatric oncology including but not limited to supporting the Viva University Children's Cancer Centre and St Jude Viva Children's cancer program. This programme aims to expand the services in paediatric oncology at the National University Health System and to establish for strategic research programs in the following fields: 1) Bone Marrow Transplant, 2) Childhood Leukaemia, 3) Bone Cancer, 4) After-Completion-of-Therapy and to set up a professorship in paediatric oncology.
- (iv) Education and Research Fund – The funds were donated by the Company to National University of Singapore to the Department of Paediatrics in support of education, training and research in paediatric oncology specifically through projects that are part of the Viva Children's Cancer Programme and income and expenses for Annual ST Jude Viva Forum in paediatric oncology. In 2013, the fund was closed and the balance of S\$78,448 was refunded to the Company.
- (v) Immunotherapy Fund – The funds were donated by the Company to Yong Loo Lin School of Medicine, National University of Singapore, to fund cancer immunotherapy clinical research, specifically to support clinical trials of novel therapies based on immune cells for children and adults with drug resistant cancer. The donation of S\$1 million was received from Lee Foundation, via Viva Foundation.
- (vi) Centre for Translational Research in Acute Leukaemia – The funds were donated by the Company to the National University of Singapore to support the advancement of education and research with the establishment of CenTRAL, a state-of-the-art leukaemia research and diagnostic facility with the key objective of improving the cure rates and quality of life of patients with leukaemia and haematologic cancer in Singapore and the Asia region, through accurate leukaemia classification, prediction and determination of treatment response. The initial fund of S\$1 million was donated from Children's Cancer Foundation, via Viva Foundation. As at 31 December 2014, this fund has not been established by National University of Singapore.

VIVA FOUNDATION FOR CHILDREN WITH CANCER
(Incorporated in Singapore)

THE FOLLOWING SUPPLEMENTARY NOTES
HAS BEEN PREPARED FOR MANAGEMENT PURPOSES ONLY
AND DOES NOT FORM PART OF THE AUDITED FINANCIAL STATEMENTS

VIVA FOUNDATION FOR CHILDREN WITH CANCER
(Incorporated in Singapore)

SUPPLEMENTARY NOTES - 31 DECEMBER 2014

A. INCOME & EXPENDITURE

	Booked in the accounts of			Matching Grants Booked in the accounts of								
	(1)	(2)	(3)	(4)	(5)	(6)	(7)	(8)	(9)	(10)	(11)	(12)
	Viva S\$'000	NUS- CCCEF S\$'000	NUH- HREF S\$'000	NUS- VPOF S\$'000	NUS- ERF S\$'000	NUS- IF S\$'000	VIVA- CenTRAL S\$'000	NUS- CCCEF S\$'000	NUH- HREF S\$'000	VIVA- -POF S\$'000	VIVA- ERF S\$'000	VIVA- PPO S\$'000
31 December 2014												
Balance as of 1 January 2014, net	27,526	1,564	3,188	7,226	-	-	-	2,653	3,000	10,144	918	5,374
Income												
1 January 2014 to												
31 December 2014	1,697	9	5	16	-	1,000	1,000	273	-	1,043	16	553
Expenditure												
1 January 2014 to												
31 December 2014	(2,105)	-	(314)	(1,417)	-	(169)	-	-	-	-	-	(24)
Refund												
1 January 2014 to												
31 December 2014	-	-	-	-	-	-	-	-	-	-	-	-
Balance as of 31 December 2014	27,118	1,573	2,879	5,825	-	831	1,000	2,926	3,000	11,187	934	5,903

- (1) Viva Foundation for Children with Cancer
(2) & (8) National University of Singapore - Children Cancer Centre Fund
(3) & (9) National University Hospital - Health Research Endowment Fund
(4) National University of Singapore - Viva Paediatric Oncology Fund
(5) National University of Singapore - Education and Research Fund
(6) National University of Singapore - Immunotherapy Fund
(7) Viva - Centre for Translational Research in Acute Leukaemia
(10) Viva - Paediatric Oncology Fund
(11) Viva - Education and Research Fund
(12) Viva - Professorship in Paediatric Oncology

VIVA FOUNDATION FOR CHILDREN WITH CANCER
(Incorporated in Singapore)

SUPPLEMENTARY NOTES - 31 DECEMBER 2014

A. INCOME & EXPENDITURE (cont'd)

	(13) = Direct S\$'000	(14) = Matching S\$'000	
Income			
Balance as of			
1 January 2014, Gross	56,128		22,092
1 January 2014 to			
31 December 2014	3,727		1,885
Balance as of 31 December 2014	59,855		23,977

Details of income booked in Viva's accounts (i) **To Dec 14**
S\$'000

Charitable activities (i.e. St. Jude - VIVA Forum)	148
Voluntary income	953
Activities for generating funds	580
Investment income	15
Others	1
Total income	1,697

VIVA FOUNDATION FOR CHILDREN WITH CANCER
(Incorporated in Singapore)

SUPPLEMENTARY NOTES - 31 DECEMBER 2014

A. INCOME & EXPENDITURE (cont'd)

	(1)	Booked in the accounts of				Matching Grants Booked in the accounts of				(10)
		(2)	(3)	(4)	(5)	(6)	(7)	(8)	(9)	
	Viva S\$'000	NUS-CCCEF S\$'000	NUH-HREF S\$'000	NUS-VPOF S\$'000	NUS-ERF S\$'000	NUS-CCCEF S\$'000	NUH-HREF S\$'000	VIVA-POF S\$'000	VIVA-ERF S\$'000	VIVA-PPO S\$'000
31 December 2013										
Balance as of 1 January 2013, net	28,310	1,549	3,183	9,026	79	2,380	3,000	9,102	824	4,824
Income										
1 January 2013 to										
31 December 2013	617	15	20	26	-	273	-	1,042	94	553
Expenditure										
1 January 2013 to										
31 December 2013	(1,401)	-	(15)	(1,826)	-	-	-	-	-	(3)
Refund										
1 January 2013 to										
31 December 2013	-	-	-	-	(79)	-	-	-	-	-
Balance as of 31 December 2013	27,526	1,564	3,188	7,226	-	2,653	3,000	10,144	918	5,374

- (1) Viva Foundation for Children with Cancer
(2) & (6) National University of Singapore - Children Cancer Centre Fund
(3) & (7) National University Hospital - Health Research Endowment Fund
(4) National University of Singapore - Viva Paediatric Oncology Fund
(5) National University of Singapore - Education and Research Fund
(8) Viva - Paediatric Oncology Fund
(9) Viva - Education and Research Fund
(10) Viva - Professorship in Paediatric Oncology

VIVA FOUNDATION FOR CHILDREN WITH CANCER
(Incorporated in Singapore)

SUPPLEMENTARY NOTES - 31 DECEMBER 2014

A. INCOME & EXPENDITURE (cont'd)

	(11) =	(12) =	
	(1)+(2)+(3)+(4)+(5)	(6)+(7)+(8)+(9)+(10)	
Direct		Matching	
S\$'000		S\$'000	
Income			
Balance as of			
1 January 2013, Gross	55,450		20,130
1 January 2013 to			
31 December 2013	678		1,962
Balance as of 31 December 2013	56,128		22,092

Details of income booked in Viva's accounts

	(i)	
		To Dec 13
		S\$'000
Charitable activities (i.e. St. Jude - VIVA Forum)	113	
Voluntary income	419	
Investment income	6	
Others	79	
Total income	617	

VIVA FOUNDATION FOR CHILDREN WITH CANCER
(Incorporated in Singapore)

SUPPLEMENTARY NOTES - 31 DECEMBER 2014

B. PLEDGES RECEIVABLE

	To be booked in the accounts of				Matching Grants To be booked in the accounts of				
	(1)	(2)	(3)	(4)	(5)	(6)	(7)	(8)	(9)
Viva		NUS- CCCEF	NUH- HREF	NUS- VPOF	NUS- ERF	NUS- CCCEF	NUH- HREF	NUS- VPOF	NUS- ERF
S\$'000		S\$'000	S\$'000	S\$'000	S\$'000	S\$'000	S\$'000	S\$'000	S\$'000
Balance at of 1 January 2014	-	-	-	-	-	-	-	-	-
Pledges written off	-	-	-	-	-	-	-	-	-
Total pledges receivable	-	-	-	-	-	-	-	-	-

31 December 2014

Balance at of 1 January 2014

Pledges written off

Total pledges receivable

$$\begin{aligned} &\text{Total Funds Received} \\ (10) = & (11) = \\ (1)+(2)+(3)+(4)+(5) & (6)+(7)+(8)+(9) \\ \text{Direct} & \text{Matching} \\ \text{S\$'000} & \text{S\$'000} \end{aligned}$$

Balance as of 1 January 2014

Pledges written off

Total pledges receivable

- (1) Viva Foundation for Children with Cancer
- (2) & (6) National University of Singapore - Children Cancer Centre Fund
- (3) & (7) National University Hospital - Health Research Endowment Fund
- (4) & (8) National University of Singapore - Viva Paediatric Oncology Fund
- (5) & (9) National University of Singapore - Education and Research Fund

VIVA FOUNDATION FOR CHILDREN WITH CANCER
(Incorporated in Singapore)

SUPPLEMENTARY NOTES - 31 DECEMBER 2014

B. PLEDGES RECEIVABLE (cont'd)

	To be booked in the accounts of				Matching Grants To be booked in the accounts of				
	(1) Viva S\$'000	(2) NUS- CCCEF S\$'000	(3) NUH- HREF S\$'000	(4) NUS- VPOF S\$'000	(5) NUS- ERF S\$'000	(6) NUS- CCCEF S\$'000	(7) NUH- HREF S\$'000	(8) NUS- VPOF S\$'000	(9) NUS- ERF S\$'000
Balance at of 1 January 2013	-	330	-	-	-	-	-	-	-
Pledges written off	-	(330)	-	-	-	-	-	-	-
Total pledges receivable	-	-	-	-	-	-	-	-	-

31 December 2013

Balance at of 1 January 2013

Pledges written off

Total pledges receivable

$$\begin{aligned} \text{Total Funds Received} \\ (10) = (11) = \\ (1)+(2)+(3)+(4)+(5) \quad (6)+(7)+(8)+(9) \\ \text{Direct} \quad \text{Matching} \\ \text{S\$'000} \quad \text{S\$'000} \end{aligned}$$

Balance as of 1 January 2013
Pledges written off
Total pledges receivable

- (1) Viva Foundation for Children with Cancer
- (2) & (6) National University of Singapore - Children Cancer Centre Fund
- (3) & (7) National University Hospital - Health Research Endowment Fund
- (4) & (8) National University of Singapore - Viva Paediatric Oncology Fund
- (5) & (9) National University of Singapore - Education and Research Fund

VIVA FOUNDATION FOR CHILDREN WITH CANCER
(Incorporated in Singapore)

SUPPLEMENTARY NOTES - 31 DECEMBER 2014

C. TOTAL AMOUNTS RAISED

	Year ended 31 December 2014	Year ended 31 December 2013
	S\$'000	S\$'000
Received		
- Direct	3,727	676
- Matching	1,885	1,962
	<u>5,612</u>	<u>2,638</u>
Pledges receivable		
- Direct	-	-
- Matching	-	-
	<u>-</u>	<u>-</u>
Total	<u>5,612</u>	<u>2,638</u>

VIVA FOUNDATION FOR CHILDREN WITH CANCER
(Incorporated in Singapore)

SUPPLEMENTARY NOTES - 31 DECEMBER 2014

D. RESOURCES AVAILABLE

	As at 31 Dec 2014		As at 31 Dec 2013			
	Expendable S\$'000	Non-Expendable (Matching Grant) S\$'000	Total S\$'000	Expendable S\$'000	Non-Expendable (Matching Grant) S\$'000	Total S\$'000
(i) RECEIVED						
Own account	27,118	-	27,118	27,524	-	27,524
NUS-CCEF	1,573	2,926	4,499	1,564	2,653	4,217
NUH-HREF	2,879	3,000	5,879	3,188	3,000	6,188
NUS-IF	831	-	831	-	-	-
VIVA-CenTRAL	1,000	-	1,000	-	-	-
VIVA-POF	5,825	11,187	17,012	7,226	10,144	17,370
VIVA-ERF	-	934	934	-	918	918
VIVA-PPO	-	5,903	5,903	-	5,374	5,374
	39,226	23,950	63,176	39,502	22,089	61,591
(ii) PLEDGES RECEIVABLE						
Own account	-	-	-	-	-	-
NUS-CCEF	-	-	-	-	-	-
NUH-HREF	-	-	-	-	-	-
NUS-VPOS	-	-	-	-	-	-
NUS-ERF	-	-	-	-	-	-
	-	-	-	-	-	-
TOTAL (i) + (ii)						
Own account	27,118	-	27,118	27,524	-	27,524
NUS-CCEF	1,573	2,926	4,499	1,564	2,653	4,217
NUH-HREF	2,879	3,000	5,879	3,188	3,000	6,188
NUS-IF	831	-	831	-	-	-
VIVA-CenTRAL	1,000	-	1,000	-	-	-
VIVA-POF	5,825	11,187	17,012	7,226	10,144	17,370
VIVA-ERF	-	934	934	-	918	918
VIVA-PPO	-	5,903	5,903	-	5,374	5,374
	39,226	23,950	63,176	39,502	22,089	61,591